New GIP Receptor Blocker Shows Promise for Obesity and Insulin Resistance
Antag Therapeutics reports AT7687 is well tolerated in humans and drives weight loss in primates when combined with cagrilintide.
Summary
Antag Therapeutics is developing AT7687, a new type of drug that blocks the GIP hormone receptor, targeting obesity and metabolic disease. Early human trials show it is safe and can be given once weekly by injection. In animal studies, combining AT7687 with another drug called cagrilintide produced significant weight loss and improved insulin sensitivity in obese, insulin-resistant primates. The company has completed Phase 1 trials and plans to begin Phase 2a studies in mid-2026. Results will be presented at the American Diabetes Association's 2026 Scientific Sessions in June. Backed by €80 million in Series A funding, this drug represents a novel approach to tackling obesity beyond existing GLP-1 therapies, with potential implications for metabolic health and longevity.
Detailed Summary
Obesity and insulin resistance are two of the most significant drivers of accelerated aging and chronic disease. A new drug candidate, AT7687, developed by Antag Therapeutics, targets the GIP receptor — a hormone pathway involved in fat storage and metabolic regulation — offering a potentially novel complement or alternative to existing obesity medications like GLP-1 agonists.
In its first-in-human Phase 1 trial, AT7687 demonstrated a favorable safety and tolerability profile in both healthy volunteers and people living with obesity. The drug is designed for once-weekly subcutaneous injection, a delivery format already familiar from popular weight-loss medications, which could support patient adherence if it advances to market.
Preclinical data add further intrigue. When AT7687 was combined with cagrilintide — a long-acting amylin analogue also being studied for weight management — obese, insulin-resistant non-human primates showed robust weight loss alongside substantial improvements in insulin sensitivity and body composition. These dual benefits are particularly relevant for longevity, as both excess adiposity and insulin resistance are independently linked to accelerated biological aging, cardiovascular disease, and type 2 diabetes.
The company plans to initiate Phase 2a clinical trials in mid-2026, which will provide the first controlled efficacy data in human patients. Antag has secured €80 million in Series A funding led by Versant Ventures, signaling strong investor confidence in the GIP antagonist mechanism as a differentiated approach in the crowded metabolic disease space.
Important caveats apply. All human data so far come from Phase 1 safety trials, not efficacy studies. The most compelling weight-loss and metabolic results are from animal models, which do not always translate to humans. Independent peer-reviewed publication of the full dataset has not yet occurred, and the ADA presentation will be the first major public disclosure of these findings.
Key Findings
- AT7687 was well tolerated in Phase 1 trials in healthy adults and people with obesity, supporting once-weekly injection.
- Combining AT7687 with cagrilintide produced robust weight loss in obese, insulin-resistant non-human primates.
- Preclinical data showed substantial improvements in insulin sensitivity and body composition alongside weight reduction.
- Phase 2a human efficacy trials are expected to begin mid-2026, marking the next critical milestone.
- €80 million Series A funding secured, signaling strong backing for GIP receptor antagonism as a metabolic therapy.
Methodology
This is a corporate news report summarizing a company press release ahead of a conference presentation. Evidence is based on Phase 1 human safety data and preclinical non-human primate studies; no peer-reviewed publication has been cited. Claims originate from Antag Therapeutics and have not yet been independently verified.
Study Limitations
All efficacy data are currently from animal models; human Phase 1 results address safety only, not weight loss or metabolic outcomes. No peer-reviewed publication is available, and conference presentations may not include full datasets. Readers should await Phase 2a results and independent analysis before drawing conclusions about clinical utility.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.